Ethics review of studies during public health emergencies - the experience of the WHO ethics review committee during the Ebola virus disease epidemic
Open Access
- 26 June 2017
- journal article
- review article
- Published by Springer Science and Business Media LLC in BMC Medical Ethics
- Vol. 18 (1), 1-11
- https://doi.org/10.1186/s12910-017-0201-1
Abstract
Between 2013 and 2016, West Africa experienced the largest ever outbreak of Ebola Virus Disease. In the absence of registered treatments or vaccines to control this lethal disease, the World Health Organization coordinated and supported research to expedite identification of interventions that could control the outbreak and improve future control efforts. Consequently, the World Health Organization Research Ethics Review Committee (WHO-ERC) was heavily involved in reviews and ethics discussions. It reviewed 24 new and 22 amended protocols for research studies including interventional (drug, vaccine) and observational studies. WHO-ERC provided the reviews within on average 6 working days. The WHO-ERC often could not provide immediate approval of protocols for reasons which were not Ebola Virus Disease specific but related to protocol inconsistencies, missing information and complex informed consents. WHO-ERC considerations on Ebola Virus Disease specific issues (benefit-risk assessment, study design, exclusion of pregnant women and children from interventional studies, data and sample sharing, collaborative partnerships including international and local researchers and communities, community engagement and participant information) are presented. To accelerate study approval in future public health emergencies, we recommend: (1) internally consistent and complete submissions with information documents in language participants are likely to understand, (2) close collaboration between local and international researchers from research inception, (3) generation of template agreements for data and sample sharing and use during the ongoing global consultations on bio-banks, (4) formation of Joint Scientific Advisory and Data Safety Review Committees for all studies linked to a particular intervention or group of interventions, (5) formation of a Joint Ethics Review Committee with representatives of the Ethics Committees of all institutions and countries involved to strengthen reviews through the different perspectives provided without the ‘opportunity costs’ for time to final approval of multiple, independent reviews, (6) direct information exchange between the chairs of advisory, safety review and ethics committees, (7) more Ethics Committee support for investigators than is standard and (8) a global consultation on criteria for inclusion of pregnant women and children in interventional studies for conditions which put them at particularly high risk of mortality or other irreversible adverse outcomes under standard-of-care.Funding Information
- not applicable (Not applicable)
This publication has 53 references indexed in Scilit:
- Ebola haemorrhagic fever outbreak in Masindi District, Uganda: outbreak description and lessons learnedBMC Infectious Diseases, 2011
- Should Sponsors and DSMBs Share Interim Results Across Trials?JAIDS Journal of Acquired Immune Deficiency Syndromes, 2011
- Recombinant Adenovirus Serotype 26 (Ad26) and Ad35 Vaccine Vectors Bypass Immunity to Ad5 and Protect Nonhuman Primates against Ebolavirus ChallengeJournal of Virology, 2011
- Risk-benefit assessment in medical research--critical review and open questionsLaw, Probability and Risk, 2010
- Single-Injection Vaccine Protects Nonhuman Primates against Infection with Marburg Virus and Three Species of Ebola VirusJournal of Virology, 2009
- Mucosal Immunization of Cynomolgus Macaques with the VSVΔG/ZEBOVGP Vaccine Stimulates Strong Ebola GP-Specific Immune ResponsesPLOS ONE, 2009
- Research Ethics and International Epidemic Response: The Case of Ebola and Marburg Hemorrhagic FeversPublic Health Ethics, 2009
- Vesicular Stomatitis Virus-Based Ebola Vaccine Is Well-Tolerated and Protects Immunocompromised Nonhuman PrimatesPLoS Pathogens, 2008
- Treatment of Marburg and Ebola hemorrhagic fevers: A strategy for testing new drugs and vaccines under outbreak conditionsAntiviral Research, 2008
- A DNA Vaccine for Ebola Virus Is Safe and Immunogenic in a Phase I Clinical TrialClinical and Vaccine Immunology, 2006